|
Published by: BCC Research
Published: Sep. 1, 2001 - 278 Pages
Table of Contents
Introduction
Study Goal And Objectives
Reasons For Doing The Study
Contributions Of The Study And For Whom
Scope And Format
Methodology
Information Sources
Related Bcc Reports
Bcc On-Line Services
Summary
Overview
The Cellular Basis Of Cancer
Causes Of Cancer
Definitions
Cancer Statistics
Worldwide Cancer Deaths
U.S. Cancer Statistics
Types Of Cancer
Breast Cancer
Cervical Cancer
Colorectal Cancer
Head And Neck Cancer
Leukemias
Liver Cancer
Lung Cancer
Hodgkin's Lymphoma
Nonhodgkin's Lymphoma
Melanoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Cost Of Diagnosing And Treating Cancer In The U.S.
Primary Treatment Modalities For Cancer
Surgery
Radiation Therapy
Radiopharmaceutical Therapy
Pharmaceutical Therapy
Chemotherapy
Main Types Of Chemotherapeutic Drugs
The Problem Of Drug Resistance
Biological Therapy
What Biological Therapies Are
Advantages Of Biological Therapies
History Of Biological Drug Development
The Development Of Biological Drugs For Cancer
Biological Response Modifiers
Endocrine Therapy
Types Of Biological Drugs For Cancer
Hyperthermia And Cryotherapy
New Technologies And Approaches To The Treatment Of Cancer
Angiogenesis Inhibitors
Background
Products In Development
Matrix Metalloproteinase Inhibitors
Tyrosine Kinase Inhibitors
Epidermal Growth Factor Inhibitor
Other Anti-Angiogenesis Agents
Monoclonal Antibodies
The Importance Of Antibody Drugs And Diagnostics
Major Technical Issues
The Hama Problem And Its Resolution
Building A Better Mouse . . .
. . . And Goat
Using Monoclonal Antibodies As Carriers For Cytotoxic Drugs
New Directions In Antibody Research
Signal Transduction Inhibitors
Telomerase Inhibitors
Thymidylate Synthase Inhibitors
Topoisomerase Inhibitors
Vaccines
Gene Therapy
Why Gene Therapy?
Delivery Of Genes As Drugs
Synthetic Vectors And Viral Vectors
Gene Expression Systems
Antisense
Products
Categories Of Products
Cytotoxic Drugs
Antimetabolites
Alkaloids
Alkylating Agents
Antibiotics
Biological Drugs
Hormones And Anti-Hormones
Innovative Products
Cancer Drugs Commonly Used In The U.S.
Recent Approvals
Aromasin
Bulsulfex
Camptosar
Ellence
Mylotarg
Nipent
Ontak
Panretin
Targretin
Temodar
Trisenox
Uvadex
Viadur
Top-Selling Cancer Drugs
The Market For Cancer Products By Therapeutic Class
Sales Of Products By Geographic Area
Drugs In Development To Treat Cancer
Cytotoxic Drugs
Innovative Cytotoxic Drugs
Xeloda
Generic Paclitaxel Approved
The Problem Of Multidrug Resistance
The Market For Cytotoxic Drugs
Cytotoxic Drugs In Development
Biological Therapy Market
Market By Product/Technology Type
Immune-Based Products
Colony-Stimulating Factors
Interferons
Interleukins
Monoclonal Antibodies
Herceptin
Panorex
Rituxan
The Market For Monoclonal Antibodies To Treat Cancer
Nonimmune-Based Products
The Market For Biological Drugs Used In The Treatment Of Cancer
Market Share Of Companies Supplying Biological Drugs For Cancer
Biological Cancer Drugs In Development
Immune-Based Therapies
Interferons
Tumor Necrosis Factor
Nonimmune-Based Therapies
Hormone Drugs
Tamoxifen—Impact Of Prophylactic Use And Generic Competition
Designer Estrogens
The Market For Hormone Drugs Used To Treat Cancer
Hormone Drugs In Development For The Treatment Of Cancer
Innovative Products
Angiogenesis Inhibitors
Monoclonal Antibodies
Monoclonal Antibody Products
3622w94
Abx-Egf
Anti-B4-Dc1
Anti-Cd15 Pm81
Anti-Cd33
Anti-Cea
Anti-Cgh
Anti-Egfr
Anti-Tissue Factor/Factor Viia
Anti-Vegf
Bec-2
Bexxar
Brevarex
C225
Campath
Cea-Cide
Ceavac
Cmb 401
Cotara
Eric-1
G250
Gliomab-H
Hctm01
Huc242-Dmi
I-125 Mab A33
Lmb-7
Lymphocide
Mdx-11
Mdx-22
Mdx-210
Mdx-220
Mdx-447
Melimmune
Monoclonal Antibody Conjugate
Monopharm C
Mrk-16
Novavac-M1
Oncolym
Oncolysin Cd6
Oncolysin S
Oncopurge
Ovarex
Prostascint
Rigscan Cr49
Smart 1d10
Smart M195/Bismuth 213 Antibody
Theragyn
Tm 27
Tnt-1
Triab
Trigem
Ttma
Vegf Receptor 2 Mab
Vitaxin
Zd 0490
Zevalin
Photodynamic Drugs
Vaccines
Gene Therapies
The Market For Gene Therapy Treatments Of Cancer
Antisense
Antisense Drugs In Clinical Trials
The Market For Innovative Cancer Therapies
New Drug Delivery Technologies
Liposomes
Wafers
Drugs In Development By Type Of Cancer
Adenocarcinoma
Detox-B Adjuvant
Bladder Cancer
Dfmo
Blood-Based Cancers
Neovastat
Brain Cancer
Gliadel
Xcytrin
Breast Cancer
Aptosyn
Caelyx/Doxil
Faslodex
Colorectal Cancer
Avicine
C225
Su5416
Gastric Cancer
Marimastat
Head And Neck Cancer
Ci-1042
Foscan
Ingn 201
Intradose
Promysin
Kaposi's Sarcoma
Leukemias
Amdray
Glivec
Ldi-200
Maxamine
Peg-Intron
Smart M195 Antibody
Tiazole
Lung Cancer
Alimta
Onconase
Melanoma
Allovectin-7
Gmk
Melacine
M-Vax
Nonhodgkin's Lymphoma
Nipent
Zevalin
Nonsmall Cell Lung Cancer
Prinomast
Tirazone
Ovarian Cancer
Hmfg1
Theragyn
Pancreatic Cancer
Gastrimmune
R115777
Rubitecan
Prostate Cancer
Abarelix
Cypat
Leuprogel
Metaret
Provenge
Renal Cell Carcinoma
Other Cancers
Mx6
Spartaject
Thymitaq
Zinecard
Industry
Leading Companies In The Cancer Drug Market
Market Leaders By Cancer Drug Category
The Pharmaceutical Industry In 2001
The Japanese Pharmaceutical Market
Leading Companies In The Worldwide Pharmaceutical Market
Speaking Of Mergers . . .
The Shrinking Period Of Market Exclusivity For Innovator Drugs
The Effect Of Generics On The Cancer Drug Market
Percentage Of The Market Held By Generic Drugs
Percentage Of Prescriptions Held By Generic Drugs
Generic Drug Market By Therapeutic Category
Patent Expirations Of Leading Anticancer Drugs
The Market For Generic Anticancer Agents
Pricing Restrictions
Drug Prices And Consumer Spending On Pharmaceuticals
Recent Happenings At The Fda
The Worldwide Regulatory Environment
Biotechnology Products Enter The Pharmaceutical Mainstream
Pending Product Approvals In The U.S.
A Steady Increase In The Number Of Biotechnology Drugs
A Biotechnology-Based Cancer Treatment Scenario In 2010, 2020 And 2040
The Future Looks Bright For The World Pharmaceuticals
Genomics Revolutionizes Drug Discovery And Future Disease Treatment
How Is Genomics Revolutionizing Healthcare?
Drug Discovery And Development
Diagnostics
Pharmacogenomics
Impact Of Pharmacogenomics On Drug Development
Competitors In Pharmacogenomics
Where Genomics Is And Where It Is Going
Genomics In Cancer Diagnostics And Monitoring
The Market For Brca1/Brca2 Testing
Profiles
Abgenix, Inc.
Aphton Corp.
Astrazeneca Plc
Bristol-Myers Squibb Co.
Corixa Corp.
Genentech, Inc.
Glaxosmithkline Plc
Idec Pharmaceuticals Corp.
Ilex Oncology, Inc.
Eli Lilly And Co.
Medarex, Inc.
Millennium Pharmaceuticals, Inc.
Myriad Genetics, Inc.
Neopharm, Inc.
Novartis Pharmaceuticals Corp.
Pharmacia Corp.
Protein Design Labs, Inc.
Appendix A: Company Names And Addresses
List Of Tables
Summary Table:
Products For Cancer Treatment: Worldwide Sales, Through 2005
1 Environmental Causes Of Cancer
2 Worldwide Incidence And Mortality Of Cancer, 2000
3 Cancer Deaths Per 100,000 Population In Selected Countries, 1994-1997
4 Incidence, Mortality, And Survival Rates For Common Cancers: U.S., 2000
5 Cancer Prevalence Rates: U.S., 2000
6 Projected New Cancer Drug Launches, 2001-2005
7 Percentage Of Patients With Egf Positive Cancers
8 Major Antisense Technologies
9 Anti-Cancer Drugs Commonly Used In The U.S.
10 Currently Marketed Cancer Drugs With Sales Exceeding $50 Million, 1999
11 Sales For Currently Marketed Cancer Drugs, 2000
12 Cancer Products By Therapeutic Class: Worldwide Sales, Through 2005
13 The Estimated Worldwide Cancer Product Market By Geographic Area, 2000
14 Cytotoxics: Worldwide Sales, Through 2005
15 Cytotoxic Agents In Phase Iii Development Or Submitted For Marketing Approval
16 Monoclonal Antibodies Used To Treat Cancer: Worldwide Sales, Through 2005
17 Biological Cancer Drugs And Their Indications
18 Biological Drugs Used To Treat Cancer: Worldwide Sales, Through 2005
19 World Market Shares And Sales For Companies Supplying Biological Cancer Drugs, 1999
20 Biological Drugs In Phase Iii Development Or Submitted For Marketing Approval
21 Hormone And Anti- Hormone Drugs Used In The U.S. For The Treatment Of Cancer
22 Hormonal Drugs Used To Treat Cancer: Worldwide Sales, Through 2005
23 Hormone Drugs In Phase Iii Development Or Submitted For Marketing Approval
24 Innovative Products In Phase Iii Development Or Submitted For Marketing Approval
25 Anti-Angiogenesis Drugs In Development
26 Angiogenesis Inhibitors: Worldwide Sales, Through 2005
27 Matrix Metalloproteinase Inhibitors: Worldwide Sales, Through 2005
28 Selected Therapeutic Antibody Products In Development For The Treatment Of Specific Cancers
29 Therapeutic Antibody Products In Development For The Treatment Of Multiple Types Of Cancer
30 Antibodies In Development For Cancer And Related Conditions
31 Cancer Vaccines In Development By Developer And Indication(S)
32 Selected Gene Therapy Clinical Trials Currently Underway For The Treatment Of Cancer
33 The Market For Cancer Gene Therapy Drugs: Through 2005
34 Selected Antisense Drug Clinical Trials With Cancer Indications Currently Underway
35 Companies Developing Antisense Drugs For The Treatment Of Cancer
36 Innovative Therapies: Worldwide Sales, Through 2005
37 Estimated Drug Launches By Type Of Cancer: Worldwide, 2000-2005
38 Selected Drugs In Phase Iii Development For Adenocarcinoma
39 Selected Drugs Phase Iii Development For Bladder Cancer
40 Selected Drugs In Phase Iii Development For Blood-Based Cancers
41 Selected Drugs In Phase Iii Development For Brain Cancer
42 Selected Drugs In Phase Iii Development For Breast Cancer
43 Selected Drugs In Phase Iii Development For Colorectal Cancer
44 Selected Drugs In Phase Iii Development For Gastric Cancer
45 Selected Drugs In Phase Iii Development For Head And Neck Cancer
46 Selected Drugs In Phase Iii Development For Kaposi's Sarcoma
47 Selected Drugs In Phase Iii Development For Leukemias
48 Selected Drugs In Phase Iii Development For Lung Cancer
49 Selected Drugs In Phase Iii Development For Melanoma
50 Selected Drugs In Phase Iii Development For Nhl
51 Selected Drugs In Phase Iii Development For Nonsmall Cell Lung Cancer
52 Selected Drugs In Phase Iii Development For Ovarian Cancer
53 Selected Drugs In Phase Iii Development For Pancreatic Cancer
54 Selected Drugs In Phase Iii Development For Prostate Cancer
55 Selected Drugs In Phase Iii Development For Renal Cell Carcinoma
56 Selected Drugs In Phase Iii Development For Other Cancers
57 Worldwide Sales And Market Share Of The Top Cancer Drug Manufacturers, 1999
58 Projected Worldwide Sales And Market Share Of The Top Cancer Drug Manufacturers, 2000
59 Market Leaders In The Four Categories Of Cancer Drugs, 1999
60 World Pharmaceutical Markets, 1999
61 Pharmaceutical Industry Mergers And Acquisitions, 1996-2000
62 Generic Market As A Percent Of The Total Prescription Market, By Country, Through 2003
63 Worldwide Generic Market Value And Percent Share, By Country, 1999 And 2005
64 1999 Sales And Patent Expiration Of Leading Anticancer Agents, 1999
65 Forecast Of The Generic Market Share Of Anticancer Drugs, U.S., Through 2005
66 Biotech Drugs Awaiting Fda Approval
67 Worldwide Sales Of Selected Biotechnology Drugs, 1999
68 The Market For Brca1/Brca2 Testing, Through 2005
69 Abgenix's Antibody Drugs In Clinical Trials
70 Abgenix' S Xenomouse Technology Collaborators
71 Astrazeneca's Anticancer Products In Development
72 Genentech's Cancer Product Portfolio
73 Idec's Collaborative Arrangements
74 Idec's Product Pipeline
75 Ilex's Product Pipeline
76 Lilly's Cancer Product Pipeline
77 Medarex's Drug Development Pipeline
78 Myriad Genetics' Gene-Based Products/Discovery Pipeline
79 Myriad Genetics' Pipeline Of Near-Term Gene Discoveries
80 Myriad Genetics' Strategic Alliances
81 Neopharm's Product Pipeline
82 Pdl's Antibody Products
List Of Figures
Summary Figure: Ratio Of Older And Newer Cancer Drugs, 2000-2005
1 Cancer Product Market Share By Country, 2000
2 Share Of Leading Competitors In The Worldwide Cancer Drug Market, 1999
3 Projected Share Of Leading Competitors In The Worldwide Cancer Drug Market, 2000
AbstractCancer remains the second-leading cause of death in the industrialized world, but the disease continues to be underserved by effective therapeutic agents. Further, many of the available agents act systemically and therefore have side effects that range from uncomfortable to life threatening. At the end of 2000, there were over 350 drugs in development for the treatment of various cancers, more than for any other disease category. Of these, more than 40 were in Phase III trials. This report discusses four primary categories of currently available cancer agents: cytotoxics, biologics (excluding vaccines), adjunct therapies and innovative therapies. Innovative therapies include such products as monoclonal antibodies, vaccines and gene therapy. Market forecasts and trends are provided for these categories. Extended discussion is provided on new technologies involved in the treatment of cancer, such as angiogenesis inhibitors, matrix metalloproteinase inhibitors, signal transduction inhibitors, antibodies to surface markers and growth factors, gene therapies and vaccines. The competitive environment is examined, with a special focus on how new products and technologies as well as acquisitions and mergers are likely to reshuffle the leading manufacturers in the cancer arena. Profiles are provided of current market leaders as well as companies with innovative products poised to enter the sector during the forecast period.
Get Full Details About This Report >>
|
